Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463134 | 1.00 | POLB (0.58) | POLBSYKNTSR1PPARAL3MBTL1 | |
| SCHEMBL7512116 | 1.00 | POLB (0.58) | POLBSYKNTSR1PPARAL3MBTL1 | |
| SCHEMBL10604129 | 0.95 | SYK (0.57) | POLBSYKNTSR1PPARAL3MBTL1 | |
| SCHEMBL31027104 | 0.95 | SYK (0.57) | POLBSYKNTSR1PPARAL3MBTL1 | |
| SCHEMBL13311348 | 0.90 | SYK (0.52) | POLBSYKNTSR1PPARAL3MBTL1 | |
| SCHEMBL11911350 | 0.89 | SYK (0.54) | POLBSYKNTSR1L3MBTL1MAPT | |
| SCHEMBL10051906 | 0.89 | SYK (0.54) | POLBSYKNTSR1L3MBTL1MAPT | |
| SCHEMBL2958129 | 0.89 | SYK (0.62) | POLBSYKATMCTSSCTSK | |
| SCHEMBL2958133 | 0.89 | SYK (0.62) | POLBSYKATMCTSSCTSK | |
| SCHEMBL18343681 | 0.88 | SYK (0.56) | POLBSYKNTSR1PPARAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016008946-A1 | NOVEL COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2975046-A1 | Novel compounds | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2016-01-20 | — | — | EP | disclosed |
| US-8637546-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV) | ABBVIE INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130059873-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC. | 2013-03-07 | — | — | US | disclosed |
| US-8119664-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-07-29 | — | — | US | disclosed |
| EP-1560811-B9 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070265302-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | MADAR DAVID J | 2007-11-15 | — | — | US | disclosed |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | MADAR DAVID J | 2007-10-11 | — | — | US | disclosed |
| US-7262207-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-08-28 | — | — | US | disclosed |
| EP-1560811-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7238724-B2 | Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis | ABBOTT LABORATORIES (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059873-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | POLB 3297/4885SYK 1899/4885NTSR1 1658/4885 |
| US-20070265302-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | POLB 3297/4885SYK 1899/4885NTSR1 1658/4885 |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | POLB 3297/4885SYK 1899/4885NTSR1 1658/4885 |
| US-20100190822-A1 | Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | POLB 3297/4885SYK 1899/4885NTSR1 1658/4885 |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | POLB 3283/4885SYK 1914/4885NTSR1 1643/4885 |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | POLB 3283/4885SYK 1914/4885NTSR1 1643/4885 |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | POLB 3297/4885SYK 1899/4885NTSR1 1658/4885 |
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | POLB 3689/4885SYK 3537/4885NTSR1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.